Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047979 · ClinicalTrials.gov registry record · Phase 2
Systems Biology of Zoster Vaccine
A Phase 2 study of Shingles and Chickenpox, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04047979: Completed Phase 2 study of Shingles and Chickenpox, sponsored by Emory University.
NCT04047979 is a Phase 2 study of Shingles and Chickenpox that has completed, run by Emory University. The registered enrollment target is 38 participants, below the 393-participant average among 6 other Shingles trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04047979, a Phase 2 study of Shingles and Chickenpox, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
Primary Outcome
Will be assessed between D0, D1, and D7 and each dose of Zoster vaccine recombinant, adjuvanted, in both age cohorts: 50-60 years and \>70 years of age. Results will be reported using Mean Normalized Enrichment Score (NES) of the Antiviral Interferon Signature Module (NES reflects the degree to which the activity level of a set of transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number
Conditions Studied
Interventions
- BIOLOGICAL Shingrix®
Study Locations (1)
Georgia
- The Hope Clinic - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 2 |
What the finished NCT04047979 record still lists
NCT04047979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 393-participant average among 6 other Shingles trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Shingles appearing as the primary indexed condition, and to 1 intervention - of which Shingrix® is the first listed.
NCT04047979 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04047979 about?
NCT04047979 is a clinical study titled "Systems Biology of Zoster Vaccine". The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
What is the current status of trial NCT04047979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2019-11-14. Estimated completion is 2023-10-30.
What conditions does trial NCT04047979 study?
This clinical trial studies the following conditions: Shingles, Chickenpox, Zoster, Zoster Varicella.
What interventions are being tested in trial NCT04047979?
The interventions under investigation include: Shingrix® (BIOLOGICAL).
Who is sponsoring clinical trial NCT04047979?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04047979 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shingles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
RECRUITING · Phase 2
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Valacyclovir in Immunocompromised Children
COMPLETED · Phase 1
-
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI